中国版诺和诺德,开始爆

艾美达医药咨询
14 May

中国版诺和诺德已经隐隐成型,华东医药现在创新药板块布局已经能看出很强的方向性。目前内分泌板块之外,华东医药有极具BD可能性的HDM2005,有正在临床阶段的PROTAC药物,还有PD-L1相关的融合蛋白。而作为主攻方向的内分泌板块,目前华东医药肉眼可见在下重注,以最近为例,其相关三靶点管线DR10624目前刚出临床I期结果就惊艳众人,它可不是减重适应症药物,而是布局了差异化的脂肪肝适应症。华东医药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10